



ANTIBODY DRUG DISCOVERY

One-Stop Integrated Service for Antibody Drug Discovery

- Comprehensive biology capability for target validation
- Integrated multiple platforms supporting reagent generation, assay development, and bioanalytical analysis
- Featured B cell cloning, hybridoma, and phage display technology for antibody lead candidate generation
- Strong antibody engineering asset for candidate optimization
- Built-in manufacturability assessment connecting discovery to CMC development
- Extensive experience in managing and delivering over 60 integrated service projects successfully


Typical Integrated Antibody Drug Discovery Flow Chart



CASE STUDY:

Phase I - Antibody Lead Candidate Generation

- Both hybridoma and phage display platforms for antibody generation
- Functional assays developed and adapted for early screening to identify potential functional candidates



CASE STUDY:

Phase II - Antibody Engineering and Candidate Selection

- Multiple panels of sequence analysis employed to reduce potential liabilities
- Optimized candidates then characterized by a variety of bio-functional and analytical assays
- Manufacturability tested to ensure late stage development
- Efficacy and PK profiling also part of candidate selection

